you are leading a team of researchers at a pharmaceutical company. your goal is to design drugs that help fight cancer. specifically, you want to focus on drugs that bind to and inactivate certain proteins, thereby halting cell cycle progression. one of your team members suggests targeting the retinoblastoma (rb) protein and inhibiting this protein. will this approach be successful? why or why not?